FDA Adverse Event Injury Summary report: N

FRAXEL RE: STORE DUAL

MDR report key: 7477890 · Received May 1, 2018

Report

Report Number
3011423170-2018-00034
Event Type
Injury
Date Received
May 1, 2018
Date of Event
November 1, 2016
Report Date
April 3, 2018
Manufacturer
SOLTA MEDICAL INC
Product Code
GEX
PMA / PMN Number
K130193
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Occupation
PATIENT

Narratives

Additional Manufacturer Narrative · 0

NO ADDITIONAL INFORMATION WAS PROVIDED BY THE TREATING PHYSICIAN. THE INVESTIGATION WAS CONDUCTED BASED ON THE INFORMATION WE RECEIVED FROM THE CUSTOMER. ACCORDING TO FRAXEL RE:PAIR USER MANUAL, POST INFLAMMATORY HYPERPIGMENTATION (PIH) OR HYPO PIGMENTATION ARE KNOWN COMPLICATIONS OF MANY LASER TREATMENTS. IN PATIENTS WHO ARE PRONE TO PIH, BLEACHING AGENTS ARE USED BEFORE AND RESUMED ONE WEEK AFTER THE TREATMENTS TO AVOID SKIN IRRITATION. PIH IS GENERALLY TRANSIENT, LASTING FROM WEEKS, UP TO 3 MONTHS. THE CONDITION WILL BE HASTENED/WORSENED IF THE PATIENT IS NOT COMPLIANT WITH SUN PROTECTION/AVOIDANCE. IN THIS PARTICULAR CASE, NO PICTURES WERE PROVIDED AND NO REPORT OF SYSTEM ISSUES DURING TREATMENT BY THE PATIENT.

Description of Event or Problem · 1

A REPORT WAS RECEIVED FROM A (B)(6) PATIENT WHO HAD A FRAXEL TREATMENT FOR ACNE DONE IN LONDON, UNITED KINGDOM. BOTH SIDES OF THE PATIENT'S FACE WERE TREATED FROM TEMPLE TO CHEEKS. THE PATIENT INDICATED THAT HE HAD BEEN INSTRUCTED BY THE DOCTOR TO USE HYDROQUINONE AND HE HAS BEEN USING IT FOR THE PAST 7 MONTHS. HOWEVER, HE STATED THAT THE LEFT HAND SIDE OF HIS FACE IS APPROXIMATELY TWO SHADES DARKER THAN THE SURROUNDING SKIN, WHILE THE TREATED AREA ON THE RIGHT SIDE IS APPROXIMATELY FIVE SHADES DARKER. WE HAVE BEEN TRYING TO CONTACT THE PHYSICIAN WHO PERFORMED THE PROCEDURE TO COLLECT ADDITIONAL INFORMATION HOWEVER, TO DATE WE HAVE BEEN UNSUCCESSFUL.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
321247 FRAXEL RE: STORE DUAL POWERED LASER SURGICAL INSTRUMENT GEX SOLTA MEDICAL INC UNKNOWN

Patients

Seq Age Sex Outcome Treatment
1